Piracetam
The prototypical racetam, in clinical use in parts of Europe for cognitive decline, myoclonus and vertigo. Evidence for cognitive benefit in healthy adults is weak and inconsistent, but it is well studied for a nootropic and has a benign safety record.
01 Overview
Piracetam, synthesised in the 1960s, gave the drug class 'racetam' and the term 'nootropic' its name. It is licensed in several European countries for cortical myoclonus and as an adjunct in dementia and dyslexia, though not approved in the United States.
Meta-analyses suggest possible benefit in age-related cognitive impairment, while trials in healthy young adults show little consistent effect. It is notable for very low toxicity, with the main drawbacks being mild and transient.
02 Mechanism
Modulates neuronal membrane fluidity and AMPA/cholinergic neurotransmission, and may improve microvascular blood flow; the precise mechanism remains incompletely defined.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Typical nootropic | 1200–4800 mg/day | Oral | Often split into 2-3 doses; clinical myoclonus dosing can reach higher. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Possible cognitive support in impairmentSome benefit in age-related decline and post-stroke aphasia; minimal in healthy young adults. | Small, population-dependent | Clinical | |
| Reduced myoclonusEstablished adjunct for cortical myoclonus. | Moderate | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| HeadacheFrequently reported, sometimes attributed to acetylcholine demand. | Mild | Common | Anecdotal | |
| Irritability / agitationOccasional restlessness or irritability, more common at higher doses. | Mild | Uncommon | Observational |